# Efficacy and Safety of GSP 301 Nasal Spray in Children (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR)

> **NCT03463031** · PHASE3 · COMPLETED · sponsor: **Glenmark Specialty S.A.** · enrollment: 446 (actual)

## Conditions studied

- Seasonal Allergic Rhinitis (SAR)

## Interventions

- **DRUG:** GSP 301 NS
- **DRUG:** GSP 301 Placebo NS

## Key facts

- **NCT ID:** NCT03463031
- **Lead sponsor:** Glenmark Specialty S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-16
- **Primary completion:** 2018-11-14
- **Final completion:** 2018-11-14
- **Target enrollment:** 446 (ACTUAL)
- **Last updated:** 2019-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03463031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03463031, "Efficacy and Safety of GSP 301 Nasal Spray in Children (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03463031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*